Navigation Links
Alexza to Report 2014 Second Quarter Financial Results on Thursday, August 7, 2014
Date:7/17/2014

MOUNTAIN VIEW, Calif., July 17, 2014 /PRNewswire/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) will report results for its fiscal quarter ended June 30, 2014 on Thursday, August 7, 2014, following the close of the U.S. financial markets. The Company will also host an investor conference call and live webcast on the same day at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time to provide a company update and discuss the financial results. 

To access the webcast via the Internet, go to www.alexza.com, under the "Investor Relations" link.  Please log onto the webcast prior to the start of the call to ensure time for any software downloads that may be required to participate in the webcast. 

LIVE CALL:
888-713-4213 or +1-617-213-4865 (international)
Passcode: 23868261
Interested parties may also pre-register for the call at: https://www.theconferencingservice.com/prereg/key.process?key=P7KJF9AQ7

REPLAY:
888-286-8010 or +1-617-801-6888 (international)
Passcode: 24951818

A replay of the conference call may also be accessed at www.alexza.com under the "Investor Relations" link. A replay of the call will be available for 14 days following the event.

About Alexza Pharmaceuticals, Inc.
Alexza Pharmaceuticals is focused on the research, development and commercialization of novel, proprietary products for the acute treatment of central nervous system conditions.  Alexza's products are based on the Staccato® system, a hand-held inhaler designed to deliver a drug aerosol to the deep lung, providing rapid systemic delivery and therapeutic onset, in a simple, non-invasive manner.

ADASUVE® is Alexza's first commercial product and it has been approved for sale by the U.S. Food and Drug Administration and the European Commission. Teva Pharmaceuticals USA, Inc. is Alexza's commercial partner for ADASUVE in the U.S. Grupo Ferrer Internacional S.A. is Alexza's commercial partner for ADASUVE in Europe, Latin America and the Commonwealth of Independent States countries.

ADASUVE® and Staccato® are registered trademarks of Alexza Pharmaceuticals, Inc.

Safe Harbor Statement
The anticipated news release and conference call will contain forward-looking statements that involve significant risks and uncertainties. Any statement describing the Company's expectations or beliefs is a forward-looking statement, as defined in the Private Securities Litigation Reform Act of 1995, and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of developing and commercializing drugs, including the ability of Alexza and its partners, Teva and Ferrer, to effectively and profitably commercialize ADASUVE, estimated product revenues and royalties associated with the sale of ADASUVE, the adequacy of the Company's capital to support the Company's operations, and the Company's ability to raise additional funds and the potential terms of such potential financings. The Company's forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements. These and other risks concerning Alexza's business are described in additional detail in the Company's Annual Report on Form 10-K for the year ended December 31, 2013 and the Company's other Periodic and Current Reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Logo - http://http://photos.prnewswire.com/prnh/20140121/SF49110LOGO


'/>"/>
SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Alexza Pharmaceuticals to Present at the 25th Annual Piper Jaffray Healthcare Conference
2. Alexza Reports 2013 Third Quarter Financial Results
3. Alexza Pharmaceuticals to Present at the Stifel Healthcare Conference 2013
4. Edison expands North American healthcare sector coverage with initiation of coverage on Alexza Pharmaceuticals
5. Alexza Reports Preliminary 2013 Second Quarter Financial Results
6. Alexza Pharmaceuticals to Present at the 2013 Wedbush Life Sciences Management Access Conference
7. Alexza Reports 2013 First Quarter Financial Results
8. Alexza Pharmaceuticals to Present at Antiepileptic Drug and Device Trials (AED) XII Conference Highlighting Advances in the Treatment of Epilepsy
9. Alexza to Report 2013 First Quarter Financial Results on Thursday, May 9, 2013
10. Alexza Reports 2012 Fourth Quarter and Full Year Financial Results
11. Peter W. Schineller Joins Alexza Pharmaceuticals as Senior Vice President and Chief Commercial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... 2016 Aethlon Medical, Inc. (Nasdaq: AEMD ), ... will be presenting at Source Capital Group,s 2016 Disruptive Growth ... at 2:15 p.m. ET on Wednesday, February 10, 2016.  ... taking place at 3:15 p.m. ET. http://www.aethlonmedical.com .  ... after the conclusion of the live event. The panel discussion ...
(Date:2/5/2016)... , February 5, 2016 ... market research report "Fetal (Labor & Delivery) and Neonatal ... Warmer, Incubator, Pulse Oximeter, Phototherapy/Jaundice Management Devices, CPAP, Capnograph, ... MarketsandMarkets, This report studies the global market over the ... estimated at USD 6.28 Billion in 2015 and is ...
(Date:2/4/2016)... Feb. 4, 2016 For hospitals considering enrollment ... already participating in the program, the Health Resources and ... as the , Mega-Guidance , could have significant impact ... published in September 2016. Essential Insights , ... Marketing , summarizes the Mega-Guidance,s key proposed changes, including ...
Breaking Medicine Technology:
(Date:2/7/2016)... ... February 07, 2016 , ... ... empowers employers and organizations with the tools and information to lower the costs, ... to cut the cost of providing employee healthcare benefits by as much as ...
(Date:2/6/2016)... ... February 06, 2016 , ... US Sports Camps is proud to sponsor ... event brings together top non-profit leaders, ultimate organizations, and coaches from around the US. ... Bay Area Disc Program Director of Youth and Education, describes this year YUCC as ...
(Date:2/6/2016)... Pekin, IL (PRWEB) , ... February 06, 2016 ... ... the recovery phases of eating disorder treatment helps to reduce the frequency and ... “Tasks of the Recovery Phase: Re-Establishing Healthy Identity and Purpose,” will explore the ...
(Date:2/5/2016)... ... February 05, 2016 , ... VeloReality ... lighter, sleeker next generation LYNX VR Indoor Trainer with multi-rider capability to an ... and manufacturing not only reduce the weight of the unit, they also enhance ...
(Date:2/5/2016)... ... 2016 , ... The event is being held on April 7, 2016 from ... Triumph Over Parkinson’s will fund nearly $100,000 for research for the care and cure ... disease and is the architect of this informative event to raise awareness and funds ...
Breaking Medicine News(10 mins):